key: cord-0870766-pftfqyai
authors: Otsuka, Shinya; Hiraoka, Kei; Suzuoki, Masato; Ujiie, Hideki; Kato, Tatsuya; Yokota, Isao; Yonezawa, Kazuya; Oguma, Keiji; Iwashiro, Nozomu; Kato, Mototsugu; Ohara, Masanori
title: Antibody responses induced by the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in a single community hospital in Japan()
date: 2021-12-30
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.12.015
sha: a8ccb7c96e399c4470d73b335986b9552f855b15
doc_id: 870766
cord_uid: pftfqyai

INTRODUCTION: The effectiveness of several vaccines against coronavirus disease (COVID-19) has been reported in the real-world setting. However, it is still unknown how long antibodies persist following vaccination and whether or not the persistence of antibodies has a protective effect against COVID-19. METHODS: Healthcare workers who had received two doses of the BNT162b2 mRNA COVID-19 vaccine were enrolled, and a single-center study was conducted at the National Hospital Organization Hakodate National Hospital. Serum samples from all participants were collected 13–21 weeks (median: 20 weeks) after the second dose of vaccination. The antibody titers were measured using an electrochemiluminescence immunoassay (Elecsys® Anti-SARS-CoV-2 S). Data on characteristics of the participants were gathered from patient records and interview sheets. RESULTS: A total of 401 participants, among whom 70.1% were women and the median age was 42 years, were evaluated in this study. None of the participants had a definite COVID-19 history, and all participants who received complete vaccination showed positive antibody titers. The antibody titer was observed to be higher in participants with younger age (p < 0.001) and those who were females (p = 0.028). Despite the higher risk of infection than that of the general public, no vaccinated staff developed breakthrough infections. CONCLUSIONS: This study demonstrates the significant contribution of the BNT162b2 vaccine in the acquisition of anti-SARS-CoV-2S antibodies; therefore, the general population should benefit from these two vaccine doses, which are expected to be protective for at least five months.

Owing to the rapid development of vaccines against coronavirus disease (COVID-19) based on a large number of studies conducted, several vaccines are currently being approved worldwide [1] [2] [3] [4] [5] [6] . Among the vaccines available for clinical use, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines are most widely used. They play a key role in managing the COVID-19 pandemic in major countries. In Japan, the BNT162b2 mRNA COVID-19 vaccine (Comirnaty®;

BioNTech and Pfizer) was the first to be approved by regulatory affairs, where its inoculation started on February 17, 2021. This was followed by the approval of the mRNA-1273 SARS-CoV-2 vaccine (Moderna) and the ChAdOx1 AZD1222 vaccine (AstraZeneca) on May 21, 2021 [1] [2] [3] . Healthcare workers were given priority for inoculation due to the extremely high risk of exposure to SARS-CoV-2 and the need to secure the country's healthcare system; thus, almost all of the said workers are already vaccinated with the BNT162b2 mRNA COVID-19 vaccine in Japan.

The promising effectiveness of the BNT162b2 mRNA vaccine has already been reported in previous research [7] . In a clinical study conducted in Israel with a nationwide mass vaccination setting, the estimated effectiveness of the BNT162b2 vaccine after full vaccination was 92% for documented infection and 87% for hospitalization rates [8] . Further, the real-world efficacy announced by the United States Center for Disease Prevention has shown that globally approved mRNA vaccines (Pfizer-BioNTech and Moderna) reduce the risk of symptomatic illness by 94% among healthcare providers after the second vaccine dose [9] . However, antibody titers reportedly decrease gradually over time J o u r n a l P r e -p r o o f post-vaccination [10] . It is still unknown how long antibodies persist following vaccination, and whether or not the persistence of antibodies confers protective immunity against COVID-19.

In this study, the researchers analyzed the antibody titers against SARS-CoV-2 spike (S) protein receptor binding domain (RBD) at least 13 weeks after the second dose of BNT162b2 vaccination in a real-world setting in healthcare workers at a single national community hospital in Japan.

The vaccination program using the BNT162b2 mRNA COVID-19 vaccine (Pfizer, NY, USA, and BioNTech, Mainz, Germany) started on March 12, 2021 , and all healthcare workers were given priority for vaccination at the National Hospital Organization (NHO) Hakodate Hospital, Japan. This is one of the first institutions in Japan in which COVID-19 vaccination was started for staff. The workers' characteristics, including age, sex, weight, height, occupation, exposure to patient with COVID-19, previous COVID-19 infection, current smoker, comorbidities, and medications received were gathered from medical records and interview sheets. Serum samples of all participants were also collected from August 3-18, 2021; that is, 13-21 weeks after the second dose of vaccination during regular staff checkup.

The study protocol was approved by the NHO Hakodate National Hospital Ethics Committee on Clinical Research (#R3-0728001) and was conducted in compliance with all applicable national and institutional regulations. All participants provided oral consent to participate in the study. Antibody titers were significantly higher in women and in younger participants even more than three months after the second dose of the vaccine. Several studies have indicated that sex and age are associated with antibody responses [11] [12] [13] , and the findings of this study are consistent with these reports. Kageyama et al. reported that the use of medications for allergies had a correlation with lower antibody titers [13] , although the results from this study showed no association. Instead, it suggested hypertension as a factor for lower antibody titers.

This study was conducted on healthy hospital staff. Only two participants were under immunosuppressive therapy, where one received treatment with methotrexate and prednisolone, and the other with 6-mercaptopurine. Their antibody titers were 739.7 and 58.8 U/mL, respectively. In addition, two other participants received antibody drugs (Adalimumab and Dupilumab), and their antibody titers were 315.5 and 243.7 U/mL, respectively. Several studies have reported that administration of immunosuppressive drugs is associated with decreased antibody reactions following COVID-19 vaccination [11, 12] . However, it was difficult to perform further statistical analysis to show the association between immunosuppressive therapy and antibody titer due to the small number of subjects in this cohort. The researchers hope that the relationship between past medical history and medications and antibody titers will be more clearly understood in the future through larger studies involving non-healthcare workers with more comorbidities. This study has several limitations. First, the results of this study may not be applicable to other populations since this is a single-center study for Japanese healthcare workers only, and the dominant variant of the virus may possibly differ with the region. Second, the antibody titers before and after the first vaccination were not measured, and the degree of increase in antibody titer caused by the first and second vaccinations is unclear. Third, the accuracy of the data could not be verified. The proponents collected most of the clinical information, such as medical history and medications, using a selfreported questionnaire. Fourth, in this study, the decrease in antibody titers could not be examined since the differences of the elapsed period from final inoculation to blood collection were relatively small. Further follow-up is required. Finally, we used an electrochemiluminescence immunoassay for measuring antibody titers. Several studies have tested the concordance of this assay with the standard neutralization assay, and such RBD-based immunoassays are suitable for monitoring the humoral immune response of post-vaccination patients [14, 15] . However, it should be noted that this assay does not detect neutralizing antibodies accurately.

In spite of these limitations, this study demonstrated the contribution of the BNT162b2 mRNA vaccine for health care workers in a community hospital in Japan. The general population should also benefit from two doses of vaccine, which are expected to be protective for at least five months. 

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

CoV-2 recombinant spike protein nanoparticle vaccine

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

BNT162b2 mRNA

Covid-19 vaccine in a nationwide mass vaccination setting

COVID-19 vaccine effectiveness study in health workers shows mRNA vaccines 94% effective

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan

COMPARISON of FIVE COMMERCIAL ANTI-SARS-COV-2 TOTAL antibodies AND IgG immunoassays AFTER VACCINATION WITH BNT162B2 MRNA

Elecsys anti-SARS-CoV-2 S assay in COVID-19 vaccination: an exploratory analysis of the mRNA-1273 phase 1 trial